Latest Updates: February 2024
Data were updated in the following topics
- Infections, PML, Malignancies, Fatalities and COVID-19: Data updated
- Pregnancy outcomes: Data updated
- Ig levels: Data updated
As of 25-Sep-2023, a total of approximately 3,294 patients with relapsing multiple sclerosis (RMS) received ofatumumab in clinical trials including the ongoing open-label extension and there was approximately 112,482 patient-years post marketing experience1
References
1. Data on File. Periodic Safety Update Report (Cut-off date: 25 March 2023); Novartis Pharma AG.
**Last update included exposure, Ig levels, PML, malignancies, fatalities, COVID-19, pregnancy, pivotal trial, references and FAQ sections